查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984130

大肠直肠癌筛检和诊断市场：按类型、产品类型、应用和最终用户划分－2026-2032年全球市场预测

Colorectal Cancer Screening & Diagnostic Market by Type, Product, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，大肠癌筛检和诊断市场价值将达到 8.3026 亿美元，到 2026 年将成长至 9.0461 亿美元，到 2032 年将达到 14.9245 亿美元，复合年增长率为 8.73%。

主要市场统计数据
基准年 2025 8.3026亿美元
预计年份：2026年 9.0461亿美元
预测年份 2032 1,492,450,000 美元
复合年增长率 (%) 8.73%

对改变大肠直肠癌筛检和诊断的临床、经济和营运趋势进行了简洁而全面的概述。

大肠直肠癌仍然是癌症发病率和死亡率的主要原因之一，随着临床医生、保险公司和患者对更便利、更准确、更经济有效的筛检和诊断方法的需求日益增长，筛检和诊断格局正在迅速变化。过去十年，非侵入性检测、影像学和分子诊断技术的进步使临床路径更加多样化，而公共卫生措施也加大了提高高风险族群筛检率的力度。因此，目前的生态系统涵盖了传统胃肠病学家以外的更广泛的相关人员，包括基层医疗提供者、诊断实验室、门诊手术中心以及专注于数位医疗和远端病人参与的供应商。

从整体观点患者偏好、技术进步、保险公司的压力以及跨部门合作如何重新定义筛检途径和实施动态。

近年来，多项协同变化正在重塑大肠直肠癌筛检和诊断的实践。首先，病人的偏好以及医疗系统接受这些偏好的能力，加速了人们对非侵入性居家筛检方法的兴趣，这些方法减少了对医疗机构检查的依赖。同时，粪便检验和血液分子检测技术的进步也促进了这一转变，旨在平衡可及性和诊断性能。其次，影像和内视镜平台在功能和舒适度方面不断改进。虽然大肠镜检查仍然是诊断的黄金标准，但CT结肠成像和高解析度内视镜检查越来越多地用于风险分层和作为替代诊断方案。

到 2025 年，美国关税政策的变化将如何影响诊断领域的采购、供应链韧性和临床部署途径？

新的关税措施和贸易政策的转变对结直肠癌筛检和诊断领域的相关人员有重大影响。进口关税的变化可能会增加CT扫描仪、内视镜等设备以及试剂盒、试剂等耗材的到岸成本，从而影响医院、门诊手术中心和诊断检查室的采购时间和资本投资决策。为此，医疗机构和经销商可能会推迟非紧急采购，优先采购可更换的耗材，或与供应商重新谈判合约以维持营运预算。

全面的細項分析揭示了类型、产品类型、应用和最终用户趋势如何决定采用、采购和临床效用。

从检测类型角度分析市场，可以发现筛检检测和粪便检验之间存在着微妙的共生关係。筛检检测包括血液检测和影像检查，而影像检查又包括大肠镜检查、CT结肠影像和乙状结肠镜检查。在这种结构中，大肠镜检查仍然是确诊和治疗性介入的首选方法，而CT结肠成像则是一种侵入性较小的影像学检查方式，尤其对那些不愿接受传统大肠镜检查的患者俱有吸引力。乙状结肠镜检查在群体筛检中的重要性正在下降，但在某些临床情况和监测通讯协定中仍然有用。血液检测是一种新的风险分层辅助工具，当与检验的预后标记结合使用时，可能会影响转诊模式。

区域分析详细说明了基础设施、政策和文化因素如何导致世界各地市场出现不同的采用模式和策略重点。

区域趋势对筛检和诊断策略的实施方式有显着影响。在美洲，完善的筛检项目、健全的检测基础设施以及鼓励预防保健的健康环境，促进了粪便检验和大肠镜检查的广泛应用；同时，私营部门的创新也在加速更先进的分子检测技术的普及。而欧洲、中东和非洲地区的情况较为复杂，既有的公共卫生筛检措施与资源分配不均并存。西方市场强调以指南为基础的筛检路径和集中式检测网络，而中东和非洲部分地区则面临检测能力不足的问题，因此更倾向于采用非侵入性、对基础设施要求较低的方法来扩大检测覆盖范围。

策略性企业展望，阐述创新、伙伴关係与证据生成如何塑造竞争定位和长期差异。

在整体竞争格局中，成熟的医疗设备和诊断公司正采取互补策略，将产品创新与合作伙伴关係建构结合。有些公司专注于改进仪器平台和内视镜的人体工学设计，以提升临床疗效和手术效率；而其他公司则优先开发先进试剂和高灵敏度耗材，例如粪便DNA检测，以扩大非侵入性筛检的覆盖范围。此外，一些专业实验室和诊断Start-Ups正在推动新的分子和血液学方法的发展，旨在将其整合到现有的临床工作流程中，并提供扩充性的检测解决方案。

采取切实可行的策略行动，加快製造商、医疗保健提供者和保险公司的采用速度，降低业务风险，并使创新与保险公司和临床优先事项保持一致。

产业领导者应优先考虑组合式策略，在投资高影响力设备的同时，兼顾扩充性的耗材解决方案，以实现广泛应用。强调模组化产品架构和灵活的服务合同，有助于製造商减少医院和门诊手术中心的采购摩擦，并帮助诊断检查室简化检测流程。同时，产生以患者疗效、成本效益和实际效用为重点的临床证据，有助于加强与支付方的谈判，并促进相关技术被纳入临床指南。儘早与健保机构和医疗技术评估机构建立持续对话，也将加速相关技术获得保险覆盖和推广应用。

本分析采用透明的混合方法研究途径，说明了生成本分析过程中采用的主要参与、证据三角验证和品质保证流程。

本分析整合了结构化混合方法的研究证据，结合了与临床专家、实验室管理人员和采购人员的初步定性访谈，以及对同行评审的临床文献和公开监管文件的系统性回顾。初步研究包括对医院、门诊手术中心、诊断检查室和研究机构进行详细访谈，以了解其营运限制、采购行为和临床偏好。次要资讯用于将临床指南、技术进步和法规环境置于特定背景下进行解读，以确保对趋势的解释与当前的实践相符。

对策略重点和循证要求进行简洁整合，这将影响大肠癌筛检和诊断的引入和影响。

大肠直肠癌筛检和诊断领域正朝着以患者为中心、实证医学为基础、营运整合的医疗模式转变。产品和服务，特别是非侵入性检测方法和耗材，有助于提高医疗服务的可近性并缓解产能瓶颈，而影像和内视镜平台则继续提供强大的诊断和治疗能力。贸易政策和采购趋势增加了策略复杂性，凸显了供应链韧性以及在生产和分销环节采取本地化策略的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：大肠直肠癌筛检和诊断市场：按类型划分

  • 筛检测试
    • 验血
    • 影像检查
      • 大肠镜检查
      • CT结肠成像
      • 乙状结肠镜检查
  • 粪便检验
    • 粪便免疫化学检查
    • 基于癒创木脂法的大便潜血试验
    • 多标靶粪便DNA检测

第九章：大肠直肠癌筛检和诊断市场：按产品划分

  • 消耗品
    • 成套工具
    • 试剂
  • 装置
    • CT扫描仪
    • 内视镜

第十章：大肠直肠癌筛检和诊断市场：按应用领域划分

  • 疾病监测
  • 早期检测
  • 预后评估

第十一章：大肠直肠癌筛检和诊断市场：按最终用户划分

  • 门诊手术中心
  • 测试机构
  • 医院
  • 研究机构

第十二章：大肠直肠癌筛检和诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：大肠直肠癌筛检与诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：大肠直肠癌筛检和诊断市场：按国家/地区划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国大肠癌筛检与诊断市场

第十六章：中国大肠癌筛检与诊断市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Clinical Genomics Technologies Pty Ltd.
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • Exact Sciences Corp.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • KARL STORZ SE & Co. KG
  • Medtronic PLC
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Novartis AG
  • Novigenix SA
  • Olympus Corporation
  • Prenetics Global Limited
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AF41

The Colorectal Cancer Screening & Diagnostic Market was valued at USD 830.26 million in 2025 and is projected to grow to USD 904.61 million in 2026, with a CAGR of 8.73%, reaching USD 1,492.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 830.26 million
Estimated Year [2026] USD 904.61 million
Forecast Year [2032] USD 1,492.45 million
CAGR (%) 8.73%

A concise but comprehensive overview of the evolving clinical, economic, and operational forces transforming colorectal cancer screening and diagnostics

Colorectal cancer remains a leading cause of cancer morbidity and mortality, and the screening and diagnostic landscape is evolving rapidly as clinicians, payers, and patients seek more accessible, accurate, and cost-effective approaches. Over the past decade, advances in noninvasive testing, imaging modalities, and molecular diagnostics have diversified clinical pathways, while public health initiatives have intensified efforts to increase screening uptake among at-risk populations. As a result, the ecosystem now includes a broader range of stakeholders beyond traditional gastrointestinal specialists, encompassing primary care providers, diagnostics laboratories, ambulatory surgical centers, and technology vendors focused on digital health and remote patient engagement.

Clinical practice guidelines continue to emphasize early detection and risk-appropriate screening, and this has spurred investment in technologies that reduce barriers to participation. Simultaneously, the healthcare delivery context has placed renewed emphasis on patient experience and operational efficiency, prompting providers to adopt stool-based testing and streamlined referral pathways that can reduce the burden on endoscopy suites. Regulatory frameworks and payer policies are adapting to accommodate new evidence, increasing the importance of robust clinical validation and real-world outcomes. Consequently, industry players must navigate a confluence of clinical, economic, and logistical factors to deliver solutions that align with evolving standards of care and stakeholder expectations.

In this environment, a strategic view that integrates the diversity of screening modalities, the segmentation of product types, and the variability of end-user settings is essential for identifying sustainable opportunities. The following sections examine the transformative shifts, regulatory and trade pressures, segmentation dynamics, regional nuances, competitive behavior, and actionable recommendations that together define the contemporary colorectal cancer screening and diagnostics domain.

An integrated view of how patient preferences, technological advances, payer pressures, and cross-sector collaboration are redefining screening pathways and adoption dynamics

The past several years have witnessed multiple converging shifts that are reshaping colorectal cancer screening and diagnostic practice. First, patient preference and system capacity have accelerated interest in noninvasive, home-based screening modalities that reduce dependency on facility-based procedures. This shift is complemented by technological progress in stool-based assays and blood-based molecular tests that aim to balance accessibility with diagnostic performance. Second, imaging and endoscopic platforms continue to improve in capability and comfort, where colonoscopy remains the diagnostic gold standard but CT colonography and enhanced endoscopic imaging are increasingly used for risk stratification and alternative diagnostic algorithms.

Concurrently, payer policies and quality metrics are exerting pressure on screening pathways to deliver measurable population health outcomes, prompting providers to implement organized screening programs and reminder systems. Diagnostics laboratories and instrument manufacturers are responding by enhancing automation, integrating digital reporting, and fostering interoperability with electronic health records to streamline workflows. Additionally, the emergence of precision oncology concepts is driving demand for diagnostics that support early detection, prognosis assessment, and personalized post-diagnostic monitoring. Lastly, cross-sector collaboration among clinical researchers, technology vendors, and health systems has accelerated evidence generation, enabling faster translation of promising assays into routine care. Together, these dynamics create an environment where scalability, demonstrated clinical utility, and operational integration determine which innovations achieve sustained adoption.

How evolving United States tariff policies for 2025 are likely to reverberate across procurement, supply chain resilience, and clinical adoption pathways in diagnostics

Emerging tariff measures and trade policy shifts have meaningful implications for stakeholders operating in the colorectal cancer screening and diagnostics space. Changes in import duties can increase the landed cost of instruments such as CT scanners and endoscopes, as well as consumables including kits and reagents, thereby influencing procurement timing and capital expenditure decisions by hospitals, ambulatory surgical centers, and diagnostics laboratories. In response, healthcare providers and distributors may delay nonurgent purchases, prioritize replaceable consumables, or renegotiate supplier contracts to preserve operating budgets.

Moreover, tariffs can amplify supply chain fragility by incentivizing suppliers to reconfigure production footprints, pursue nearshoring, or source alternative component vendors. This reconfiguration can lead to transitional disruptions in availability and lead times. To mitigate these effects, manufacturers often accelerate localization of assembly or partner with domestic suppliers, a process that can introduce short-term cost increases but ultimately enhance resilience. Clinically, any procurement delays or cost pressures may shift the balance toward lower-resource, minimally invasive screening options that maintain throughput while limiting capital strain.

Finally, tariff-driven cost pressures also interact with reimbursement policies and payer negotiations. Health systems and diagnostics providers will need to demonstrate cost-effectiveness and operational value more rigorously when facing higher acquisition costs. As a result, organizations that proactively model scenarios, diversify supply chains, and engage in strategic sourcing partnerships will be better positioned to preserve access to advanced diagnostics while managing the financial implications of evolving trade policy.

Comprehensive segmentation synthesis revealing how type, product, application, and end-user dynamics determine adoption, procurement, and clinical utility

Analyzing the market through the lens of testing type reveals nuanced coexistence between Screening Tests and Stool Tests, where Screening Tests encompass Blood Tests and Imaging Tests, and Imaging Tests include Colonoscopy, CT Colonography, and Flexible Sigmoidoscopy. Within this structure, Colonoscopy retains primacy for definitive diagnosis and therapeutic intervention, while CT Colonography serves as a less invasive imaging alternative particularly attractive to patients averse to traditional colonoscopy. Flexible Sigmoidoscopy has diminished in prominence for population screening, yet it remains relevant in specific clinical contexts and surveillance protocols. Blood Tests are an emerging adjunct for risk stratification and may influence referral patterns when coupled with validated prognostic markers.

From a product perspective, the distinction between Consumables and Instruments shapes adoption dynamics. Consumables, comprising Kits and Reagents, are central to scaling stool-based and molecular testing programs because they support decentralized specimen collection and laboratory automation. Instruments, notably CT Scanners and Endoscopes, represent longer-term capital investments and require coordinated scheduling, maintenance, and clinician training. Consequently, organizations that offer integrated consumable supply and instrument support tend to secure deeper penetration across clinical settings.

Application segmentation-Disease Monitoring, Early Detection, and Prognosis Assessment-highlights how different technologies align with distinct clinical needs. Early Detection remains the principal driver of population screening initiatives, leveraging fecal immunochemical tests and multitarget stool DNA testing to maximize participation, whereas Disease Monitoring and Prognosis Assessment increasingly rely on molecular assays and, in some cases, blood-based biomarkers to manage post-treatment surveillance and personalize follow-up intervals. The end-user landscape composed of Ambulatory Surgical Centers, Diagnostics Laboratories, Hospitals, and Research Institutes further influences product selection; for example, diagnostics laboratories favor high-throughput kits and reagents, hospitals prioritize integrated instrument ecosystems with strong service agreements, ambulatory surgical centers emphasize throughput and patient flow for endoscopic procedures, and research institutes focus on innovative assays and clinical validation for emerging modalities.

Understanding these intersecting segmentation dimensions clarifies where investment and clinical evidence will yield the greatest impact. Products that bridge consumable convenience with robust analytical performance, supported by service models that reduce operational friction for end users across settings, will be best positioned to influence standard practice and sustain adoption.

Regional analysis detailing how infrastructure, policy, and cultural factors drive differentiated adoption patterns and strategic priorities across global markets

Regional dynamics exert a powerful influence on how screening and diagnostic strategies are implemented. In the Americas, organized screening programs, strong laboratory infrastructure, and payer environments that reward preventive care have supported broad use of stool-based tests and colonoscopy, while private sector innovation has accelerated adoption of higher-complexity molecular assays. Meanwhile, Europe, the Middle East & Africa presents a heterogeneous landscape where established public health screening initiatives coexist with resource variability; western European markets emphasize guideline-driven screening pathways and centralized laboratory networks, whereas parts of the Middle East & Africa face capacity constraints that favor noninvasive, low-infrastructure approaches for expanding access.

Asia-Pacific exhibits a rapid pace of technology adoption and a growing emphasis on population health initiatives, with several countries investing in endoscopy capacity and molecular diagnostics to address rising cancer burdens associated with demographic shifts. In many markets across this region, digital health solutions and mobile outreach are leveraged to increase screening uptake, and local manufacturing partnerships are increasingly common to support regional supply chains. Across all regions, the interplay between regulatory approvals, reimbursement frameworks, and clinician training determines the speed and scale of adoption. Ultimately, stakeholders seeking to expand presence or deploy new technologies must tailor strategies to regional policy priorities, infrastructure readiness, and cultural factors that influence patient participation in screening programs.

Strategic corporate outlook explaining how innovation, partnerships, and evidence generation are shaping competitive positioning and long-term differentiation

Across the competitive landscape, established medical device manufacturers and diagnostics companies are pursuing complementary strategies that blend product innovation with alliance building. Some organizations concentrate on refining instrument platforms and endoscope ergonomics to enhance clinical outcomes and procedure efficiency, while others prioritize the development of high-sensitivity consumables such as advanced reagents and stool DNA assays aimed at broadening noninvasive screening uptake. Additionally, a cohort of specialty laboratories and diagnostic startups is advancing novel molecular assays and blood-based approaches designed to integrate with existing clinical workflows and provide scalable testing solutions.

Partnerships between device manufacturers, laboratory networks, and digital health providers have become a common pathway to accelerate market access and clinical validation. These collaborations enable bundled offerings that include test kits, laboratory processing, reporting platforms, and patient outreach tools, thereby addressing key barriers to screening adherence. Mergers and acquisitions remain a strategic lever for companies seeking to secure complementary capabilities, expand geographic reach, or internalize critical supply components. Furthermore, regulatory milestones and the generation of real-world evidence are decisive in differentiating competitive positioning, as payers and providers increasingly demand robust performance data and clear value propositions for new diagnostics. As competition intensifies, companies that can demonstrate interoperability, clinical utility, and operational support across diverse care settings will be best placed to capture long-term clinical and commercial relevance.

Practical strategic actions for manufacturers, providers, and payers to accelerate adoption, de-risk operations, and align innovations with payer and clinical priorities

Industry leaders should prioritize a portfolio approach that balances investments in high-impact instruments with scalable consumable solutions that enable broad reach. By emphasizing modular product architectures and flexible service agreements, manufacturers can reduce procurement friction for hospitals and ambulatory surgical centers while enabling diagnostics laboratories to streamline throughput. In parallel, targeted clinical evidence generation focused on patient outcomes, cost-effectiveness, and real-world utility will strengthen negotiations with payers and support guideline inclusion. Establishing early and sustained dialogue with reimbursement authorities and health technology assessment bodies will also expedite pathways to coverage and adoption.

To mitigate trade and supply risks, organizations should diversify supplier bases and consider regional manufacturing or assembly hubs that reduce exposure to tariff volatility. Engaging in strategic partnerships with local distributors and research centers can accelerate market entry and ensure cultural alignment in outreach campaigns. Operationally, investing in digital platforms that facilitate patient reminders, remote specimen tracking, and seamless laboratory reporting will enhance adherence rates and clinician satisfaction. Finally, companies should cultivate clinician champions and collaborative pilot programs that demonstrate workflow integration, patient acceptability, and downstream clinical benefits. Together, these actions will create a resilient, evidence-backed approach to expanding the adoption of effective colorectal cancer screening and diagnostic solutions.

Transparent mixed-methods research approach describing primary engagement, evidence triangulation, and quality assurance processes used to generate the analysis

The analysis synthesizes evidence from a structured mixed-methods approach combining primary qualitative engagement with clinical experts, laboratory directors, and procurement leaders alongside systematic review of peer-reviewed clinical literature and public regulatory documents. Primary research included in-depth interviews to capture operational constraints, procurement behaviors, and clinical preferences across hospitals, ambulatory surgical centers, diagnostics laboratories, and research institutes. Secondary sources were used to contextualize clinical guidelines, technological trajectories, and regulatory environments, ensuring interpretation of trends aligned with contemporary practice.

Data triangulation techniques were applied to reconcile findings from diverse information streams, and iterative validation with domain experts refined thematic conclusions and recommendations. The segmentation framework was mapped against modality characteristics, product types, clinical applications, and end-user workflows to produce actionable insights tailored to decision-making contexts. Limitations were acknowledged where data heterogeneity or regional variance reduced comparability, and sensitivity checks were conducted to ensure that conclusions reflect robust directional trends rather than single-source signals. Quality assurance procedures included expert review cycles and cross-validation of clinical claims against authoritative guideline statements to preserve factual accuracy and relevance for stakeholders.

A concise synthesis of the strategic priorities and evidence-based imperatives that will govern adoption and impact in colorectal cancer screening and diagnostics

The colorectal cancer screening and diagnostics landscape is transitioning toward more patient-centric, evidence-driven, and operationally integrated models of care. Noninvasive modalities and consumable-centric offerings are expanding access and alleviating capacity constraints, while imaging and endoscopic platforms continue to offer definitive diagnostic and therapeutic capabilities. Trade policy and procurement dynamics add another layer of strategic complexity, underscoring the importance of supply chain resilience and localized approaches to manufacturing and distribution.

For stakeholders across the value chain, success will hinge on the ability to demonstrate clinical utility, operational value, and alignment with reimbursement priorities. Companies that build interoperable solutions, invest in rigorous clinical and real-world evidence, and cultivate collaborative partnerships with providers and payers will secure enduring advantage. At the same time, health systems that adopt organized screening programs, leverage digital engagement, and optimize procedural capacity can improve participation rates and downstream outcomes. The coming phase will reward those who couple technical innovation with pragmatic execution, ensuring that advances in diagnostics translate into measurable improvements in population health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Colorectal Cancer Screening & Diagnostic Market, by Type

  • 8.1. Screening Tests
    • 8.1.1. Blood Tests
    • 8.1.2. Imaging Tests
      • 8.1.2.1. Colonoscopy
      • 8.1.2.2. CT Colonography
      • 8.1.2.3. Flexible Sigmoidoscopy
  • 8.2. Stool Tests
    • 8.2.1. Fecal Immunochemical Test
    • 8.2.2. Guaiac-Based Fecal Occult Blood Test
    • 8.2.3. Multitarget Stool DNA Testing

9. Colorectal Cancer Screening & Diagnostic Market, by Product

  • 9.1. Consumables
    • 9.1.1. Kits
    • 9.1.2. Reagents
  • 9.2. Instruments
    • 9.2.1. CT Scanners
    • 9.2.2. Endoscopes

10. Colorectal Cancer Screening & Diagnostic Market, by Application

  • 10.1. Disease Monitoring
  • 10.2. Early Detection
  • 10.3. Prognosis Assessment

11. Colorectal Cancer Screening & Diagnostic Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Diagnostics Laboratories
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Colorectal Cancer Screening & Diagnostic Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Colorectal Cancer Screening & Diagnostic Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Colorectal Cancer Screening & Diagnostic Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Colorectal Cancer Screening & Diagnostic Market

16. China Colorectal Cancer Screening & Diagnostic Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Agilent Technologies, Inc.
  • 17.8. Bayer AG
  • 17.9. Becton, Dickinson and Company
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. bioMerieux SA
  • 17.12. Bristol-Myers Squibb Company
  • 17.13. Clinical Genomics Technologies Pty Ltd.
  • 17.14. Eiken Chemical Co., Ltd.
  • 17.15. Epigenomics AG
  • 17.16. Exact Sciences Corp.
  • 17.17. F. Hoffmann-La Roche Ltd.
  • 17.18. Fujifilm Holdings Corporation
  • 17.19. GE HealthCare Technologies, Inc.
  • 17.20. Guardant Health, Inc.
  • 17.21. Hologic, Inc.
  • 17.22. Illumina, Inc.
  • 17.23. KARL STORZ SE & Co. KG
  • 17.24. Medtronic PLC
  • 17.25. Merck KGaA
  • 17.26. Myriad Genetics, Inc.
  • 17.27. Novartis AG
  • 17.28. Novigenix SA
  • 17.29. Olympus Corporation
  • 17.30. Prenetics Global Limited
  • 17.31. QIAGEN N.V.
  • 17.32. Quest Diagnostics Incorporated
  • 17.33. Sanofi SA
  • 17.34. Siemens AG
  • 17.35. Sysmex Corporation
  • 17.36. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 178. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 179. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 208. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 209. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 216. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 218. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)